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It is known (1, 2) that certain immunogenic tumors evoke the generation of a state
ofT cell-mediated antitumor immunity in their syngeneic hosts. Nonetheless, these
tumors continue to grow progressively to kill the hosts, because host immunity un-
dergoes progressive decay after the tumor grows beyond a certain size. There is evi-
dence that the decay of host concomitant immunity is caused by the negative regula-
tory influence of tumor-induced suppressor T cells. It has been shown (3, 4), for
example, that the progressive decay of concomitant immunity after a certain stage
of tumor growth is associated with the progressive acquisition of T cells capable,
on passive transfer, of suppressing the expression of adoptive immunity against an
established tumor in appropriate test recipients. Causal evidence that these suppressor
T cells are responsible for the inadequacy of antitumor immunity was provided by
the demonstrations (5, 6) that their preferential destruction by exposing the tumor-
bearing host to a sublethal dose of ionizing radiation can result in the generation
of an increased level of immunity and in spontaneous tumor regression.
In the case of several of the tumors under study in this laboratory (4, 5), including
the L5178Y lymphoma (7), tumor-induced suppressor T cells have been shown to
display the CD4+ CD8 - surface phenotype. It might be expected, therefore, that
treating tumor-bearing mice with an anti-CD4 mAb capable of depleting the CD4+
T cell subset (8) would result in tumor regression. This expectation could only be
realized, however, if the T cell effectors of antitumor immunity did not also belong
to the CD4+ T cell subset. In other words, treatment with anti-CD4 mAb would
only cause tumor regression if antitumor immunity were expressed exclusively or
predominantly by CD8+ T cells.
The purpose of this paper is to show that treatment of mice bearing the L5178Y
lymphoma with anti-L3T4 mAb results in the elimination of CD4' T cells and in
complete, immunologically mediated regression of the tumor by CD8+ T cells. The
results provide an additional demonstration that removal of CD4+ suppressor T
cells can result in complete regression of an established immunogenic tumor.
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Materials and Methods
Mice.
￿
Female B6D2F1 (C57BL/6 x DBA/2) adult mice (10-12 wk of age) were obtained
from the Trudeau Institute Animal Breeding Facility (Saranac Lake, NY). They were reared
under barrier-sustained conditions and were shown to be free ofmost common viral pathogens
according to tests routinely performed by the diagnostic testing services of Charles River
Professional Services, Wilmington, MA.
Tumors.
￿
The L5178Y lymphoma and P815 mastocytoma, both syngeneic in DBA/2 mice,
were passaged in DBA/2 mice as ascites, harvested, cryopreserved over liquid nitrogen, and
prepared for implantation as described previously (9). The origin of these tumors has also
been described in previous publications (9). For experiments, 106 tumor cells in 0.05 ml of
PBS were implanted intradermally in the belly region, just below the sternum, and their
growth or regression was monitored by measuring changes against time in the mean of two
diameters measured at right angles.
Passive Transfer ofImmunity.
￿
Donor mice were immunized against the P815 mastocytoma
or L5178Y lymphoma as described previously (10). Briefly 2 x 106 tumor cells admixed with
100 pg formalin-fixed Propionibacterium acnes (supplied by the Trudeau Institute) were implanted
intradermally in the belly region. This method of immunization results in 9 d of progressive
tumor growth followed by complete tumor regression (10). Donor mice were used either on
day 9 oftumor growth at the onset of regression (active immune donors) or 30 d later (memory
immune donors), well after the tumor had been rejected (11). Spleens of immunized mice
were diced into small pieces, gently pushed through stainless screen into PBS containing
1% FCS, triturated with a pasteur pipette to break up clumps, and filtered through sterile
gauze to remove debris. The cells were then washed twice in PBS and resuspended in PBS
and injected via a tail vein.
Recipient mice were made T cell deficient (TXB), in order to remove a T cell suppressor
barrier to adoptive immunization as described previously (12). Briefly, mice were thymec-
tomized at 4 wk of age and exposed 1 wk later to 900 rad of whole-body y irradiation gener-
ated by a' 3'Cs irradiator (3M Company, St. Paul, MN) that delivered a mid-phantom dose
rate of 30 rad/min. They were infused intravenously with 10' syngeneic bone marrow cells
1 h after irradiation and used in experiments no sooner than 4-6 wk later. For convenience,
in some experiments the recipients were treated with cyclophosphamide (Cy)' (Mead-
Johnson, Evansville, IN) to remove the suppressor barrier to adoptive immunity (7, 13) . The
Cy was dissolved in physiological saline and injected intravenously in a dose of 150 mg/kg.
It has been shown that the L5178Y lymphoma is Cy resistant (7).
Preparation of Antibodies.
￿
Hybridoma GK1 .5 (Dr. Frank Fitch, University of Chicago,
Chicago, IL) producing anti-L3T4 mAb, and hybridomas 30-H12 and TIB-210 (American
Type Culture Collection, Rockville, MD) producing antiThy-1 .2 mAb and anti-Ly-2.2 mAb,
respectively, were grown as ascites in the pristane-primed peritoneal cavities of sublethally
irradiated (500 rad) BALB/c mice. The ascites fluid was harvested in heparinized syringes,
transferred to tubes, and centrifuged to remove cells. The content of rat IgG in the cell-free
fluid was quantified by radial immunodiffusion. Anti-L3T4 IgG was present at 6 mg/ml,
whereas anti-Lyt-2.2 IgG and antiThy-1.2 IgG were present at 10 and 10.8 mg/ml, respec-
tively. Antibody-containing ascites fluid was stored at -20°C. To obtain rat anti-Lyt-2
(nonallelic), and mouse anti-I-Ad and anti-H-213d mAb, hybridomas TIB-105, FIB-3, and
HB-102 (American Type Culture Collection), respectively, were grown to 106 cell/ml in RPMI
1640 (Gibco Laboratories, Grand Island, NY) containing 10° 70 FCS, 2 mM glutamine, and
antibiotics. The antibody-containing supernatants were separated from cells by centrifuga-
tion and stored at -20°C.
Depletion of T Cell Subsets.
￿
In vitro depletion of T cell subsets was achieved by incubating
2 x 10' spleen cells/ml with the appropriate mAb (from ascites) at 5 pg/ml in RPMI-FCS
for 20 min at 4°C . The cells were then treated for 1 h at 37°C with an equal volume of a
1 :10 dilution of rabbit serum as a source of complement.
To achieve in vivo depletion of a T cell subset, mice that were thymectomized at 7 wk
of age were infused intravenously 3-5 wk later (while bearing a L5178Y lymphoma) with
' Abbreviation used in this paper: Cy, Cyclophosphamide.AWWAD AND NORTH
￿
2195
a single 1-mg dose of the appropriate mAb. The extent of depletion was determined by flow
cytofluorometry (FACScan; Becton Dickinson & Co., Sunnyvale, CA) of spleen cells treated
with FITC-conjugated antiThy-1.2 IgG, anti-Lyt-2.2 IgG, or anti-L3T4 IgG. Conjugation
of antibody and FITC (Sigma Chemical Co., St. Louis, MO) was performed according to
a method described by Hudson and Hay (14). Spleen cells from antibody-treated or untreated
mice were stained by incubating them at 10'/ml with the appropriate FITC-conjugated mAb
at a concentration of 15 ug/ml in PBS containing 1% BSA and 0.02% sodium azide (PBS-
BSA-Azide), for 40 min at 4°C. The cells were then washed twice with sheath buffer (Clay
Adams, Parsippany, NJ), and subjected to flow cytofluorometric analysis. The results were
recorded as logio fluorescence against the number of cells stained.
To determine the surface phenotype of the L5178Y lymphoma, tumor cells from a perito-
neal ascites were stained directly with FITC-conjugated antiThy-1 .2 IgG or anti-L3T4 IgG
as described for spleen cells above. To test for the presence of Lyt-2.1, the cells were incubated
with anti-Lyt-2 (hybridoma TIB-105) for 40 min at 4°C, washed, and then incubated with
FITC-conjugated goat anti-rat IgG (Cappel Laboratories, Cochranville, PA) for 40 min at
4°C. They were also examined for surface I-A and H-2D by incubating them with anti-I-
A' mAb or mouse anti-H-213d mAb, respectively, for 40 min at VC, and then with FITC-
conjugated goat anti-mouse IgG Ab (Cappel Laboratories) for 40 min at 4°C . The mAb
supernatants were used at a dilution of 1 :5, and the FITC-conjugated second antibodies were
used at 20 ug/ml. The cells were then washed twice in sheath buffer and subjected to flow
cytofluorometric analysis.
Results
Depletion of L3T4+ T Cells with Anti-L3T4 mAb Results in Spontaneous Tumor Regres-
sion. Previous studies with the L5178Y lymphoma (5) and other tumors (7) showed
that progressive tumor growth results in the generation of L3T4+ suppressor T cells
capable of suppressing antitumor immunity in an adoptive immunity assay. They
showed, in addition, that the preferential elimination of these suppressor cells by
exposing the host to sublethal ionizing radiation can result in spontaneous tumor
regression (5, 6). Moreover, because pilot studies had shown (see later), in the case
of the L5178Y lymphoma, that host immunity is mediated and expressed predomi-
nantly by Lyt-2 + T cells, it was anticipated that in vivo removal of all L3T4+ T
cells from mice bearing this tumorwith anti-L3T4 mAb should result in the removal
of suppressor T cells and consequently in the generation of a large enough number
of tumor-sensitized Lyt-2+ T cells to cause complete tumor regression.
Fig. 1 shows the results of an experiment that tested the effect on the L5178Y lym-
phoma growing in thymectomized mice of an intravenous infusion of 1 mg of anti-
L3T4 mAb, 1 mg of anti-Lyt-2 mAb, or 1 mg of both antibodies, on day 9 of tumor
growth. It can be seen that treatment with anti-L3T4 mAb resulted in complete
tumorregression and in long-term (>90 d) host survival. In contrast, treatment with
anti-Lyt-2 mAb, or with both mAbs, resulted in a striking enhancement of tumor
growth and in greatly decreased host survival time.
That treatment with mAbs eliminated the appropriate T cell subset is evidenced
by the results of flow cytofluorometric analysis ofthe spleens oftreated mice as shown
in Fig. 2 . At the time of onset of tumor regression, >98% of L3T4+ T cells and
>98% of Lyt-2+ T cells were removed by treatment with anti-L3T4 mAb and anti-
Lyt-2 mAb, respectively.
Because the L5178Y tumor is a T cell lymphoma, it is possible that the therapeutic
effect of anti-L3T4 mAb was caused by direct destruction ofthe tumor by the mAb.
However, a flow cytofluorometric examination of appropriately stained L5178Y cells2196
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FIGURE 1 .
￿
An intravenous injection (arrow) of 1 mg of rat anti-L3T4 mAb (aL3T4) into B6D2
mice bearing a day9L5178Y lymphoma results in complete tumorregression (left), and in long-
term host survival (right). In contrast, intravenous injection of 1 mg anti-Lyt-2 .2 mAb (aLy2),
or both antibodies (aLy2 + aL3T4) resulted in a striking enhancement of tumor growth (left)
and in a significant reduction in host survival time (right). Means of five mice per group.
(Fig. 3) showed that L5178Y lymphoma cells are Thy-1.2 + , H-213d, L3T4- , Lyt-
2- , and I-Ad- . This evidence, plus that presented below, leaves no doubt that anti-
L3T4 mAb has no direct effect on L5178Y cells in vivo.
Anti-L3T4 mAb Is not Therapeutic Against the L5178YLymphoma Growing in an Irradi-
ated Host. If, as indicated by the foregoing results, the therapeutic action of anti-
L3T4 mAb is mediated indirectly by an augmented level of host antitumor immu-
nity, mAbtreatment should notbe therapeutic againsttheL5178Y lymphoma growing
in a host whoseimmune system has been ablated by whole-body ionizing radiation.
Fig. 4 shows that a 9-d L5178Y lymphoma growing in mice exposed to 900 rad of
y radiation 1 d before tumor implantion failed to undergo regression in response
to treatmentwith anti-L3T4 mAb on day 9. There can be no doubt, therefore, that
anti-L3T4 mAb does not directly affect growth of the L5178Y lymphoma.
Anti-L3T4 mAb-inducedRegression Is Associated with Presence ofLyt-2+ T Cells Capable
ofPassively TransferringAntitumorImmunity. Theforegoingresults show that anti-L3T4
mAb treatment of mice bearingawell-established L5178Y lymphoma results in com-
plete tumor regression, whereastreatment with anti-Lyt-2 mAb results in a striking
enhancement of tumor growth. It was logical to anticipate, therefore, that tumor
regression would prove to be associated with the possession by the host of tumor-
sensitized Lyt-2+ T cells. This was investigated by testing the ability of T cells from
mice in the processof causing regression oftheir L5178Y tumors in response to anti-
L3T4 mAb to cause, on passive transfer, regression of a L5178Y tumor in appro-
priate recipient mice. The experiment involved giving anti-L3T4 mAb on day 9LOG10 FL INTENSITY -"
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￿
Evidence that treatingthymectomized tumorbearerswith 1mganti-L3T4mAbresulted
in depletionof L3T4* T cells, andthat treatment with 1 mg of anti-Lyt-2 mAbresulted in deple-
tion of Lyt-2* T cells. Shown are the results of a flow cytofluorometrie examination of spleen
cells from untreated tumorbearers (A), anti-L3T4-treatedtumorbearers (B), and Lyt-2-treated
tumorbearers (C), andanti-L3T4- andanti-Lyt-2-treated tumorbearers (D)stained with FITC-
conjugated antiThy-1.2 IgG, anti-L3T4 IgG, or anti-Lyt-2.2 IgG. Before antibody treatment
thespleen cell population contained 14-15% L3T4* Tcells and8-9% Lyt-2' T cells, butcon-
tained <0.5% L3T4' T cellsand Lyt-2' T cells after treatment with the appropriate antibody.
of tumor growth and harvesting spleen cells for passive transfer 5 d later. The an-
titumor action of these spleen cells was compared with that of spleen cells harvested
from control donors bearing a 14-d progressive tumor. Recipient mice were given
a 150 mg/kg dose of Cy 1 h before receiving spleen cells, in order to remove a sup-
FIGURE 3.
￿
Results ofaflow cytofluorometricexamination
ofthe surface phenotype of cells ofthe L5178Y lymphoma
grownas aperitoneal ascites andstainedwith theindicated
FITC-conjugated antibodies. It can be seen that the sur-
face of L5178Y cells were H-2Dd', Thy-1.2`, L3T4-,
Lyt-2.1-, I-Aa-. Thevery smallnumberofL3T4' cells de-
tected almost certainly were host peritoneal lymphocytes.2198
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treated, instead ofTXB recipients, because the L5178Yis known tobe a Cy-resistant
tumor (7).
Fig. 5 shows that, whereasspleen cells from anti-L3T4 mAb-treated donors caused
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FIGURE 4.
￿
Anti-L3T4 mAb had no direct in vivo effect
on theL5178Y lymphoma. An intravenous injection (arrow)
of 1 mg of mAb failed to cause regression of the tumor
growingin lethally irradiated (900 rad) mice. Meansoffive
mice per group.
FIGURE 5. Spleen cells (one
organ equivalent) from day 14
tumorbearerstreatedwith 1 mg
anti-L3T4mAb5d earlier (on
day 9 of tumor growth) were
capable, on passive transfer
(arrow), of causing complete
regression of a 4-d tumor in
recipients. In contrast, one
organequivalent ofspleen cells
from untreated day 14 tumor
bearers caused only a tem-
porary reduction in tumor
growth. In these experiments
therecipients were treatedwith
a 150 mg/kgdose ofCy 1 h be-
fore receivingdonorcells to re-
move aT cell barrier to adop-
tive immunization. Means of
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20 -complete regression of the recipient tumor, spleen from control donors had very
little antitumoreffect. As was expected, the spleen cells from anti-L3T4mAb-treated
donors that caused regression of the recipient tumor were Lyt-2+ T cells, as evi-
denced by theirfunctional eliminationby treatment with anti-Lyt-2 .2 mAb andcom-
plement, but not with anti-L3T4 mAb and complement (Fig. 6).
Anti-LM mAb Treatment Is not Therapeutic Against the P815 Mwtocytoma.
￿
It was
considered important to determine next whether the above results with the L5178Y
lymphoma could be obtained with another immunogenic tumor. The therapeutic
action of anti-L3T4 mAb treatment against an established P815 mastocytoma was
therefore tested. It was found (Fig. 7) that injecting 1 mg of anti-L3T4 mAb into
mice bearing a 9-d P815 mastocytoma had no effect on tumor growth or on host
survival time. Aflow cytofluorometric analysis ofspleen cells from thesemice showed,
in agreement with results obtained wtih spleen cells from mice bearing the L5178Y
lymphoma, that the mAb removed >98% of the T cell subset against which it was
directed (results not shown).
L3T4' T Cells Are Involved in Immunity to the P815 Mastocytoma, but not the L5178Y
Lymphoma. Theresults show that the P815 mastocytoma, in contrast to theL5178Y
lymphoma, is not responsive to therapy with anti-L3T4 mAb. The possibility that
needed to be tested, therefore, was that immunity to the P815 mastocytoma, but notthe
L5178Y lymphoma, relies to a considerable degree on the participation of L3T4+
T cells. This involved determiningwhethermice responding to immunization with
the P815 mastocytoma, but not the L5178Y lymphoma, acquire tumor-sensitized
L3T4+ T cells, as well as tumor-sensitized Lyt-2 ` T cells capable of passively trans-
ferring immunity. In these experiments mice were immunized by intradermal im-
plantation of an admixture of 2 x 106 living tumor cells and 100 leg of formalin-
fixed P. acnes. It is known (10) that implanting this admixture results in 9-10 d of
progressivetumor growth followed by complete tumor regression andin the acquisi-
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FIGURE 6.
￿
Evidence that the antitumor ac-
tivity of spleen cells from anti-L3T4
mAb-treated tumorbearers resides in theLyt-
2' T cell subset. The ability of an infusion
(arrow)ofoneorganequivalent of spleen cells
harvestedfrom anti-L3T4mAb-treatedmice
during tumor regression to cause regression
ofarecipient tumorwaseliminated by treating
thespleen cells with anti-Lyt-2 mAb and Q,
butnot with anti-L3T4 mAb andC. Means
of five mice per group.
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￿
The P815 mastocytoma failed to undergo regression in response to treatment with
anti-L3T4 mAb. Treatmentof mice bearingaday 9 P815 mastocytoma with 1 mg of anti-L3T4
mAb (arrow) had no effect on tumor growth (left), or on host survival time (right). Means of five
mice per group.
tion ofimmunity to atumor implant. It is also known (9, 11)that the onset of tumor
regression is temporally associated with thepresence in thehost of augmented numbers
of activated immune T cells capable of passively transferring antitumor immunity,
and that activated T cells are subsequently replaced by memory T cells capable of
passively transferring immunity (11).
It can be seen in Fig. 8 that the ability of spleen cells from mice generating a
therapeutic level of active immunity (immediately preceding tumor regression on
day 9) to the P815 mastocytoma to cause regression of a 3-4-mm diam P815 tumor
in appropriate recipients was eliminated by treating the cells with anti-L3T4 mAb
and complement, or with anti-Lyt-2 mAb and complement. Fig. 8 also shows that
when anti-L3T4 mAb-treated and anti-Lyt-2 mAb-treated spleen cells were added
together and infused into tumor-bearing recipients, complete tumor regression en-
sued. Therefore, in mice generating active immunity to the P815 mastocytoma, T
cells of both phenotypes are involved in immunity. Memory immunity to the P815
mastocytoma apparently was different, in that the T cells from memory-immune
donors capableof causingregression ofthe recipient tumorwere functionally elimi-
nated by treatment with anti-L3T4 mAb and complement, but not by anti-Lyt-2
mAb and complement (Fig. 9). It will be noted, with regard to the difference be-
tween active andmemory immune Tcellsthat, whereasactive immune Tcellscaused
tumor regression to commence shortly after cell transfer, memory T cells caused
tumorregression only afteradelayof 6-8d. This is in keepingwith previously pub-
lished results (11) .
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Figs. 10 and 11 show that P . aches-augmented immunity to theL5178Y lymphoma
was different from that generated againstthe P815 mastocytoma, in that it was pas-
sively transferred exclusively by Lyt-2 * T cells in all cases tested. Thus, the ability
of spleen cells harvested on day 9 of growth of a P aches-containing L5178Y lym-
phoma(justbefore theonsetof tumorregression), as well as ofspleen cellsharvested
DAY!
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Fir,URE 8. Active immunity, acquired by
mice in the process of causing regression of
theirP815 mastocytoma in response to thead-
juvant action ofintralesionalP . achesis medi-
ated by both Tcell subsets. The ability of1.5
organ equivalents (2 x 108) of spleen cells
(IMM) from these mice to cause, on passive
transfer (arrow), regression ofa4-dtumor in
Y-irradiated recipients was eliminated by
treatment with anti-L3T4 mAb and C`
(IMMaL3T4), or with anti-Lyt-2 mAb and
C' (IMMaLy2). Passive transfer of cells re-
mainingafteranti-Lyt-2 mAbtreatmentplus
thoseremainingafteranti-L3T4mAbtreat-
ment (IMMaLy2 + IMMaL3T4) resulted
complete tumorregression. Meansof five
ice per mouse.
FicURE 9.
￿
Evidence that regression of
the P815 mastocytoma by spleen cells
from memory-immune (30 d after
P aches-induced tumor regression)
donors is mediated mainly by L3T4*
T cells. The capacity of 1.5 spleen
equivalents (1.8 x 108) of cells from
thesedonors to cause complete regres-
sion of a recipient tumor was elimi-
nated by treatment with anti-L3T4
mAb, but notwith anti-Lyt-2 mAbor
C' . In this experiment the recipients
were T cell-deficient (TXB) mice
bearinga4-dtumor. It should be noted
that tumor regression did not com-
mence until aftera 6-d delay. Means
of five mice per group.2202
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>30 d later (memory immunity), to cause regression of an L5178Y tumor in recip-
ient mice was totally eliminated by treating thecells with anti-Lyt-2 mAb and com-
plement, but not by treating them with anti-L3T4 mAb and complement (Figs. 10
and 11).
Discussion
This study confirms the results of previous investigations (2) showing that mice
bearingcertain immunogenic tumors generate suppressor T cells capable of down-
regulating the antitumor immune response, and that preferential removal of these
suppressor Tcellscanresult in spontaneoustumorregression (5, 6). Previous studies
(5, 6) showed that suppressor T cells are of the L3T4 phenotype and that they can
be preferentially eliminated by subjecting thehost to a sublethal dose of wholebody
y radiation. The present study represents a more convincing example of the ther-
apeutic consequences of selectively eliminating L3T4' suppressor T cells from a
tumor-bearing host. It showsthat intravenous injection ofasingle 1-mg dose of anti-
L3T4 mAb on day 9 of growth of the L5178Y lymphoma (when the tumor was 8
mm in diameter) resulted, after a 2-3-d delay, in complete tumor regression and
in long-termhost survival. It shows, in addition, that tumorregression wasnotcaused
by the direct effect of anti-L3T4 mAb on the tumor, in that the L5178Y lymphoma
provied to be L3T4- , and tumor regression failed to occur in lethally irradiated
tumorbearers treated with anti-L3T4mAb. It is apparent, therefore, that anti-L3T4
mAb-induced tumor regression was immunologically mediated. Moreover, because
the antibody removed practically all L3T4' T cells, without reducing the number
of Lyt-2' T cells, it follows that immunity must have been exclusively mediated by
Lyt-2' T cells.140 -
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FIGURE 11.
￿
Memory immunitygeneratedagainst theL5178Y lymphoma andpossessedby mice
30 d after complete regression of their tumor in response to intralesional P. aches is mediated
exclusively by Lyt-2* Tcells. Theability of 1.5 organ equivalents (1.8 x 108) of spleen cells from
thesemice (IMM) to catuse complete regression ofa4-d tumor in T cell-deficient recipient mice
was eliminated by treatment with anti-LyF2 mAb (FMMaLy2), but not with anti-L3T4 mAb
and Ey (IMMaL,3T4). Means of five mice per group.
In fact, in contrast to findings published from otherlaboratories (15-19) showing
that regression ofcertain other tumors in adoptively immunized recipients is achieved
predominantly by L3T4+ T cells, regression of the L5178Y lymphoma was shown
here to be mediated exclusively by Lyt-2+ T cells, regardless of the procedure used
to evoke immunity_ Thus, active immunity possessed by ahost in theprocessofcausing
regression of its L5178Y lymphoma in response to the adjuvant action of intrale-
sional P . ames, as well as memory immunity possessed by a host long after the com-
pletion of regression, was passively transferred with T cells that were susceptible
to treatment with anti-Lyt-2 mAb and complement, but resistant to treatment with
anti-L3T4 mAb and complement.
This was not the case for immunity to the P815 mastocytoma, however, which
failed to undergo regression after treatment with anti-L3T4 mAb. An investigation
of the T cells that mediate P . acnes-augmented active immunity to this tumor, and
of the T cells that carry immunologic memory, revealed that L3T4+ T cells, as well
as with Lyt-2+ T cells, needed to be infused in order for immunity to be passively
transferred. In this regard immunity to theP$15 mastocytoma is similar to that gener-
ated against other tumors (15-19). This does not mean, however, that the L5178Y
lymphoma is unique in terms of the immunity it evokes, although it may prove rep-
resentative of only a small proportion of immunogenic tumors. Even if this proved2204
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to be thecase, it would nottake away from the importance ofthe L5178Y lymphoma
model for showing that immunogenic tumors can evoke the generation of L3T4'
suppressor T cells, on the one hand, and that removal of these suppressor T cells
can result in spontaneous tumor regression on the other.
To this point in time, in vivo treatment with anti-L3T4 mAb apparently has not
been used to eliminate suppressor T cells. Instead, it has been used to remove
L3T4' effector T cells with the aim of preventing the development of spontaneous
(20, 21) or experimentally induced (22) autoimmune diseases, andof preventing the
rejection of tissue and organ allografts (23, 24). A likely exception to this use is seen
with murine leishmaniasis, where it has been demonstrated (25, 26) that treatment
of highly susceptible BALBlc mice with anti-L3T4 mAb enables these mice to re-
solve infection with Leishmania major. Because there is evidence (27) that BALBIc
mice are susceptible to leishmaniasis, and because they generate Lyt-1' 2- sup-
pressor T cells in response to infection, it seems highly likely that the therapeutic
effect of anti-L3T4 mAb is based on its ability to remove L3T4' suppressor T cells.
According to the interpretation given above, this would allow Lyt-2' T cells to ex-
pand in number and express immunity.
Regardless ofwhether this proves to be the reason for susceptibility to leishmani-
estated in conclusion that the evidence presented here makes it difficult
to ignore a possible role for suppressor Tcells in determining thelevel of immunity
generated in response to certain tumors and other replicating antigens.
Summary
This study shows that intravenous injection of 1 mg of anti-L3T4 mAb (GK1.5)
into thymectomized mice bearing the syngeneic L5178Y lymphoma results, after
adelayof2-3 d, in complete regression of this tumor andin long-termhost survival.
A flow cytofluorometric examination ofthe spleen cellsofmAb-treated mice revealed
that antibody treatment resulted in the elimination of >9870 of L3T4' T cells, but
had no effect on the Lyt-2' T cells subset. Tumor regression was immunologically
mediated, because L5178Y lymphoma cells were shown to be L3T4- , and regres-
sion of the tumor failed to occur in mice that had been lethally irradiated before
anti-L3T4 mAb was given. Tumor regression was mediated by tumor-sensitized Lyt-
2' T cells, as evidenced by the finding that treatment of tumor-bearing mice with
anti-Lyt-2 mAb alone, or in combinationwith anti-L3T4mAb, resulted in enhance-
ment of tumor growth and a significant decrease in host survival time. Moreover,
the spleens of mice whose tumors were undergoing regression in response to anti-
L3T4 mAb treatment contained Lyt-2' T cells capable, on passive transfer, of
causing regression of a tumor in recipient mice. These results can be interpreted
as showing that removal of tumor-induced L3T4' suppressor T cells results in the
release of Lyt-2' effector T cells from suppression, and consequently in the gener-
ation of enough Lyt-2' T cell-mediated immunity to cause tumor regression. This
can only be achieved, however, if immunity to the tumor is mediated exclusively
by Lyt-2' T cells, as is the case for the L5178Y lymphoma. In the case of the P815
mastocytoma, treatment with anti-L3T4 mAbwas without a therapeutic effect, and
this was in keeping with the finding that immunity to this tumor is mediated by
L3T4', as well by Lyt-2' T cells.We express our appreciation to Ronald LaCourse, Lynn Ryan, and Debra Duso for expert
technical support, and to Mary Durett for typing the manuscript.
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